Peptomyc is awarded €5 million from the Horizon Europe EIC Accelerator Program to conduct a Phase 1b clinical trial with OMO-103 in patients and scale up its manufacturing process

by Peptomyc

5 months ago
Peptomyc, Horizon Europe, European Innovation Council (EIC) Accelerator Program, metastatic pancreatic cancer

The biotech company Peptomyc S.L. announced today that it has been awarded €5 million blended financing from the Horizon Europe, European Innovation Council (EIC) Accelerator Program. The grant will...

VHIO spin-off Peptomyc receives approval to initiate its Phase Ib trial testing Omomyc in patients with metastatic pancreatic cancer

by VHIO

9 months ago
Pancreatic ductal adenocarcinoma (PDAC), MYC, Peptomyc, Omomyc

Peptomyc has received full study approval for its Phase Ib clinical trial evaluating the combination of its first-in-class MYC inhibitor Omomyc (OMO-103) with standard of care in metastatic pancreatic...

Progress in the maturity of the start-ups: the clinical phases

by GENESIS Biomed

3 years ago
start-ups, Oxolife, Peptomyc, aptaTargets, GENESIS Biomed, clinical phases, drug

The start-ups Oxolife, Peptomyc and aptaTargets, with which GENESIS Biomed collaborates, are advancing in their maturity with the initiation and development of clinical phases and are approaching an e...

Inbiomotion and Peptomyc receive funding through European Horizon 2020 program

by Biocat

8 years ago
Horizon 2020, start-ups, Inbiomotion, Peptomyc

In the final round of selection, the European Horizon 2020 has chosen two Catalan start-ups from the health sector: Inbiomotion and Peptomyc, which will receive €50,000 to fund their innovative proj...